Initiatives for enhancing the Canadian Clinical Research Environment

We are in a global leadership position in areas that include basic and translational research:





Canadian Initiatives to Boost Clinical Research





STRENGTHENING CLINICAL TRIALS FOR CANADIANS RENFORCEMENT DES ESSAIS CLINIQUES POUR LES CANADIENS

CANADIAN CLINICAL TRIALS COORDINATING CENTRE (CCTCC)

Kathryn Nijssen Initiatives Manager

www.cctcc.ca knijssen@cctcc.ca





HealthCareCAN

Leading, Innovation, Together,

SoinsSanté

www.cctcc.ca | info@cctcc.ca







3rd meeting NOV 2016



NATIONAL ADVISORY GROUP

 pan-Canadian expert group providing input & advice on CCTCC's activities

PROVINCIAL CT ORGANIZATIONS' MEETINGS

- Foster collaboration
- Engage for projects
- Identify emerging issues
- Prevent duplication of effort





Provincial CT Organizations Meetings



COLLABORATION





3rd meeting NOV 2016

Research Ethics Boards Issues CCTCC & HC Response Released JAN 2017 **Canadian Clinical Trials Metrics**

WHAT IS THE CCTAM?



- Web-based, 'living, easily searchable, interactive database of Canadian clinical research capabilities:
 - investigators, clinical research sites, hospitals, institutions, research ethics boards, CROs, SMOs, etc.
- First pan-Canadian, pan-therapeutic, up-to-date, research inventory with an integrated map-based search function
- Currently over 1100 assets (40% asset growth since launch in June 2015)
- Access the CCTAM by visiting <u>www.cctam.ca</u>

www.cctam.ca | cctam@cctcc.ca





Canadian Clinical Trials Asset Map (CCTAM)



CCTAM webinars available upon request.



CCTAM

Canadian Clinical Trials Asset Map



PATIENT REGISTRIES



CCTAM

- Populating in the CCTAM to facilitate CT feasibility studies & patient recruitment
- Key criteria used in selecting registries:
 - ✓ Active registry
 - ✓ 10 registrants min.
 - ✓ Point of contact
 - ✓ Diagnosis identified by an approved care team
 - ✓ Data accessible to external parties for purposes of CT recruitment
- Actively working to contact and populate in the CCTAM



MODEL CLINICAL TRIAL AGREEMENT (mCTA)

- Canada-wide initiative to:
 - standardize CT agreements by developing language for all clauses
 - ✓ bring efficiencies to clinical research process
- Collaboration with CLEAR (TransCelerate-supported) project to incorporate CLEAR language within the mCTA

mCTA

mCTA's Team Canada consists of site/institution & sponsor representatives



mCTA – CURRENT STATUS

- Adoption and Implementation stage after comprehensive stakeholder consultations in 2015 & 2016
- Reviewed by an independent legal counsel¹ for consistency of terminology use & definitions, & clarifying ambiguous wording
- mCTA Version 8, consultation report & communication deck are available for use
- Working with sponsors and sites to establish a review committee that will ensure the continued relevance of the contract

mCTA- STATUS



FAIR MARKET VALUE (FMV) PROJECT

• Direct result of the model CT Agreement (mCTA) project

✓ Goals:

- Reduction of clinical trial (CT) budget negotiation times
- Reduction of CT study start-up timelines
- Introduction of CT efficiencies and streamlining of budget negotiations

FINV

✓ Reasons to tackle FMV:

- Address increasing CT start-up times
- Ensure Canada's CT competitiveness globally



FMV BACKGROUND – STUDY START-UP

- Canada start-up is competitive compared to Europe for CV but not for Oncology trials
- Challenges with start-up in Canadian institutions (IRB, contracts, budgets)



FMV BACKGROUND



CONTRACT TIMELINES

Average Time for Contract Execution 2015-2016



CONTRACT TIMELINES





"Clinical Trials – the Canadian Advantage" Investment Case

- Consistent narrative communicating Canada's clinical trials advantages globally focused on:
 - ✓ Speed
 - ✓ Quality
 - ✓ Incentives
- Intended for presentations to global offices of CT sponsors
- Customizable based on audience's needs
- Next steps:
 - Possible additional modules
 - ✓ Keep content updated
- Access <u>here</u>







Clinical Research Participation Survey Engage. Listen. Act.

Hosted at www.bccrin.ca/survey

- First pan-Canadian survey enabling patients & healthy volunteers to provide input & advice on their CT experience
- Anonymous, online experience survey by Clinical Trials BC (formerly BCCRIN). Part of the BC Academic Health Science Network
- Pan-Canadian Expansion supported by the CCTCC
- Adults, or parents of a child, who have been invited to participate in a clinical trial and either enrolled, declined or did not meet the screening requirements are eligible
- Part of a broader strategy to engage Canadians in the clinical research process
- Data will be used to improve recruitment and retention outcomes for clinical research sites, investigators and sponsors by developing strategies designed to address provincial and national research participant perspectives and concerns

Clinical Research Participation Survey Update October 2017

- Enrollment target of > 1000 reached April 2017
- Analysis by CHEOS commenced September 2017
- Results expected November 2017
- Planned publication
- Knowledge translation planning has commenced
- **Questions**: Alison Orth at Clinical Trials BC aorth@bcahsn.ca



RESEARCH ETHICS BOARD REPORT

- The impact of the Canadian experience of REB centralization & harmonization
- Recommendations for the future to ensure Canada's competitiveness on a global scale
- CCTCC & Health Canada prepared a joint response to the WG's report
- More information is available <u>here</u>





CLINICAL TRIALS METRICS

- Quantitative metrics, e.g.:
 - ✓# of newly randomized subjects, opened sites, trials, trials by phase in Canada & globally (phases I,II,II, IV, other)
- Operational metrics, e.g.:
 - ✓ average time/days to REB approval, contract & budget
- Quality metrics, e.g.:
 - ✓ patient recruitment, validity, retention, & protocol & dosing deviations (international comparison)

CT METRICS

• Investment metrics, e.g.:

 total CT Investment in Canada (by province) vs. other countries (including CROs)



CONTACT US

WEB: www.cctcc.ca EMAIL: knijssen@cctcc.ca Phone: 613-875-3457







